{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:12:13Z","timestamp":1780553533704,"version":"3.54.1"},"publisher-location":"Cham","reference-count":231,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030695897","type":"print"},{"value":"9783030695903","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/10_2020_132","type":"book-chapter","created":{"date-parts":[[2020,9,15]],"date-time":"2020-09-15T18:16:12Z","timestamp":1600193772000},"page":"319-354","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Impact of Protein Glycosylation on the Design of Viral Vaccines"],"prefix":"10.1007","author":[{"given":"Kathleen","family":"Sch\u00f6n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Lepenies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Goyette-Desjardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,16]]},"reference":[{"key":"132_CR1","first-page":"77","volume-title":"Essentials of glycobiology","author":"A Varki","year":"2015","unstructured":"Varki A, Gagneux P (2015) Chapter 7 \u2013 Biological functions of glycans. In: Varki A, Cummings RD, Esko JD et al (eds) Essentials of glycobiology, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 77\u201388","edition":"3"},{"issue":"4","key":"132_CR2","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.tibtech.2016.10.002","volume":"35","author":"T Johannssen","year":"2017","unstructured":"Johannssen T, Lepenies B (2017) Glycan-based cell targeting to modulate immune responses. Trends Biotechnol 35(4):334\u2013346","journal-title":"Trends Biotechnol"},{"issue":"2","key":"132_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1021\/cr940283b","volume":"96","author":"RA Dwek","year":"1996","unstructured":"Dwek RA (1996) Glycobiology: toward understanding the function of sugars. Chem Rev 96(2):683\u2013720","journal-title":"Chem Rev"},{"issue":"7","key":"132_CR4","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/glycob\/cwy021","volume":"28","author":"I Bagdonaite","year":"2018","unstructured":"Bagdonaite I, Wandall HH (2018) Global aspects of viral glycosylation. Glycobiology 28(7):443\u2013467","journal-title":"Glycobiology"},{"issue":"10","key":"132_CR5","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.bbagen.2019.05.012","volume":"1863","author":"Y Watanabe","year":"2019","unstructured":"Watanabe Y, Bowden TA, Wilson IA et al (2019) Exploitation of glycosylation in enveloped virus pathobiology. Biochim Biophys Acta 1863(10):1480\u20131497","journal-title":"Biochim Biophys Acta"},{"issue":"23","key":"132_CR6","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1002\/1873-3468.13177","volume":"592","author":"I Bagdonaite","year":"2018","unstructured":"Bagdonaite I, Vakhrushev SY, Joshi HJ et al (2018) Viral glycoproteomes: technologies for characterization and outlook for vaccine design. FEBS Lett 592(23):3898\u20133920","journal-title":"FEBS Lett"},{"key":"132_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.coviro.2015.02.002","volume":"11","author":"M Crispin","year":"2015","unstructured":"Crispin M, Doores KJ (2015) Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design. Curr Opin Virol 11:63\u201369","journal-title":"Curr Opin Virol"},{"key":"132_CR8","first-page":"99","volume-title":"Essentials of glycobiology","author":"P Stanley","year":"2015","unstructured":"Stanley P, Taniguchi N, Aebi M (2015) Chapter 9 \u2013 N-glycans. In: Varki A, Cummings RD, Esko JD et al (eds) Essentials of glycobiology, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 99\u2013111","edition":"3"},{"issue":"10","key":"132_CR9","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1517\/14712598.2015.1069271","volume":"15","author":"M Dicker","year":"2015","unstructured":"Dicker M, Strasser R (2015) Using glyco-engineering to produce therapeutic proteins. Expert Opin Biol Ther 15(10):1501\u20131516","journal-title":"Expert Opin Biol Ther"},{"issue":"24","key":"132_CR10","doi-asserted-by":"publisher","first-page":"10457","DOI":"10.1007\/s00253-018-9430-6","volume":"102","author":"SK Gupta","year":"2018","unstructured":"Gupta SK, Shukla P (2018) Glycosylation control technologies for recombinant therapeutic proteins. Appl Microbiol Biotechnol 102(24):10457\u201310468","journal-title":"Appl Microbiol Biotechnol"},{"issue":"6","key":"132_CR11","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/bit.26567","volume":"115","author":"Q Wang","year":"2018","unstructured":"Wang Q, Chung CY, Chough S et al (2018) Antibody glycoengineering strategies in mammalian cells. Biotechnol Bioeng 115(6):1378\u20131393","journal-title":"Biotechnol Bioeng"},{"key":"132_CR12","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.3389\/fimmu.2018.02485","volume":"9","author":"MJ Buettner","year":"2018","unstructured":"Buettner MJ, Shah SR, Saeui CT et al (2018) Improving immunotherapy through glycodesign. Front Immunol 9:2485","journal-title":"Front Immunol"},{"issue":"4","key":"132_CR13","doi-asserted-by":"publisher","first-page":"43R","DOI":"10.1093\/glycob\/12.4.43R","volume":"12","author":"RG Spiro","year":"2002","unstructured":"Spiro RG (2002) Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds. Glycobiology 12(4):43R\u201356R","journal-title":"Glycobiology"},{"issue":"2","key":"132_CR14","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00418-016-1526-4","volume":"147","author":"A Corfield","year":"2017","unstructured":"Corfield A (2017) Eukaryotic protein glycosylation: a primer for histochemists and cell biologists. Histochem Cell Biol 147(2):119\u2013147","journal-title":"Histochem Cell Biol"},{"key":"132_CR15","first-page":"239","volume-title":"Essentials of glycobiology","author":"N Zachara","year":"2015","unstructured":"Zachara N, Akimoto Y, Hart GW (2015) Chapter 19 \u2013 the O-GlcNAc modification. In: Varki A, Cummings RD, Esko JD et al (eds) Essentials of glycobiology, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 239\u2013251","edition":"3"},{"issue":"1","key":"132_CR16","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1146\/annurev.bi.54.070185.003215","volume":"54","author":"R Kornfeld","year":"1985","unstructured":"Kornfeld R, Kornfeld S (1985) Assembly of asparagine-linked oligosaccharides. Annu Rev Biochem 54(1):631\u2013664","journal-title":"Annu Rev Biochem"},{"issue":"19","key":"132_CR17","doi-asserted-by":"publisher","first-page":"11211","DOI":"10.1016\/S0021-9258(18)60451-X","volume":"264","author":"I Brockhausen","year":"1989","unstructured":"Brockhausen I, Hull E, Hindsgaul O et al (1989) Control of glycoprotein synthesis. Detection and characterization of a novel branching enzyme from hen oviduct, UDP-N-acetylglucosamine:GlcNAc beta 1-6 (GlcNAc beta 1-2)Man alpha-R (GlcNAc to Man) beta-4-N-acetylglucosaminyltransferase VI. J Biol Chem 264(19):11211\u201311221","journal-title":"J Biol Chem"},{"issue":"42","key":"132_CR18","doi-asserted-by":"publisher","first-page":"32598","DOI":"10.1074\/jbc.M004673200","volume":"275","author":"T Taguchi","year":"2000","unstructured":"Taguchi T, Ogawa T, Inoue S et al (2000) Purification and characterization of UDP-GlcNAc: GlcNAcbeta 1-6(GlcNAcbeta 1-2)Manalpha 1-R [GlcNAc to Man]-beta 1, 4-N-acetylglucosaminyltransferase VI from hen oviduct. J Biol Chem 275(42):32598\u201332602","journal-title":"J Biol Chem"},{"issue":"5","key":"132_CR19","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/glycob\/cwj079","volume":"16","author":"T Watanabe","year":"2006","unstructured":"Watanabe T, Ihara H, Miyoshi E et al (2006) A specific detection of GlcNAcbeta1-6Manalpha1 branches in N-linked glycoproteins based on the specificity of N-acetylglucosaminyltransferase VI. Glycobiology 16(5):431\u2013439","journal-title":"Glycobiology"},{"issue":"10","key":"132_CR20","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1074\/mcp.RA119.001534","volume":"18","author":"M Nakano","year":"2019","unstructured":"Nakano M, Mishra SK, Tokoro Y et al (2019) Bisecting GlcNAc is a general suppressor of terminal modification of N-glycan. Mol Cell Proteomics 18(10):2044\u20132057","journal-title":"Mol Cell Proteomics"},{"issue":"7","key":"132_CR21","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/glycob\/cwx034","volume":"27","author":"M Schneider","year":"2017","unstructured":"Schneider M, Al-Shareffi E, Haltiwanger RS (2017) Biological functions of fucose in mammals. Glycobiology 27(7):601\u2013618","journal-title":"Glycobiology"},{"issue":"81","key":"132_CR22","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3389\/fbioe.2018.00081","volume":"6","author":"L Montero-Morales","year":"2018","unstructured":"Montero-Morales L, Steinkellner H (2018) Advanced plant-based glycan engineering. Front Bioeng Biotechnol 6(81):81","journal-title":"Front Bioeng Biotechnol"},{"issue":"10","key":"132_CR23","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.2174\/138945007782151360","volume":"8","author":"X Shi","year":"2007","unstructured":"Shi X, Jarvis DL (2007) Protein N-glycosylation in the baculovirus-insect cell system. Curr Drug Targets 8(10):1116\u20131125","journal-title":"Curr Drug Targets"},{"key":"132_CR24","first-page":"335","volume-title":"Essentials of glycobiology","author":"M Tiemeyer","year":"2015","unstructured":"Tiemeyer M, Nakato H, Esko JD (2015) Chapter 26 \u2013 Arthropoda. In: Varki A, Cummings RD, Esko JD et al (eds) Essentials of glycobiology, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 335\u2013349","edition":"3"},{"key":"132_CR25","first-page":"151","volume-title":"Essentials of glycobiology","author":"RS Haltiwanger","year":"2015","unstructured":"Haltiwanger RS, Wells L, Freeze HH et al (2015) Chapter 13 \u2013 Other classes of eukaryotic glycans. In: Varki A, Cummings RD et al (eds) Essentials of glycobiology, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 151\u2013160","edition":"3"},{"key":"132_CR26","first-page":"1","volume-title":"Essentials of glycobiology","author":"A Varki","year":"2015","unstructured":"Varki A, Kornfeld S (2015) Chapter 1 \u2013 Historical background and overview. In: Varki A, Cummings RD, Esko JD et al (eds) Essentials of glycobiology, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 1\u201318","edition":"3"},{"issue":"1","key":"132_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1742-4658.2009.07429.x","volume":"277","author":"PH Jensen","year":"2010","unstructured":"Jensen PH, Kolarich D, Packer NH (2010) Mucin-type O-glycosylation - putting the pieces together. FEBS J 277(1):81\u201394","journal-title":"FEBS J"},{"key":"132_CR28","volume-title":"Essentials of glycobiology","author":"JD Marth","year":"1999","unstructured":"Marth JD (1999) Chapter 8 \u2013 O-glycans. In: Varki A, Cummings R, Esko J, Freeze H, Hart G, Marth J (eds) Essentials of glycobiology, 1st edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor","edition":"1"},{"key":"132_CR29","first-page":"113","volume-title":"Essentials of glycobiology","author":"I Brockhausen","year":"2015","unstructured":"Brockhausen I, Stanley P (2015) Chapter 10 \u2013 O-GalNAc glycans. In: Varki A, Cummings RD, Esko JD et al (eds) Essentials of glycobiology, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 113\u2013123","edition":"3"},{"issue":"7","key":"132_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.tibs.2015.04.004","volume":"40","author":"AP Corfield","year":"2015","unstructured":"Corfield AP, Berry M (2015) Glycan variation and evolution in the eukaryotes. Trends Biochem Sci 40(7):351\u2013359","journal-title":"Trends Biochem Sci"},{"key":"132_CR31","first-page":"161","volume-title":"Essentials of glycobiology","author":"P Stanley","year":"2015","unstructured":"Stanley P, Cummings RD (2015) Chapter 14 \u2013 Structures common to different glycans. In: Varki A, Cummings RD, Esko JD et al (eds) Essentials of glycobiology, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 161\u2013178","edition":"3"},{"issue":"6","key":"132_CR32","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1128\/jvi.64.6.2841-2848.1990","volume":"64","author":"E Fenouillet","year":"1990","unstructured":"Fenouillet E, Gluckman JC, Bahraoui E (1990) Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1. J Virol 64(6):2841\u20132848","journal-title":"J Virol"},{"issue":"5","key":"132_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.tim.2007.03.003","volume":"15","author":"DJ Vigerust","year":"2007","unstructured":"Vigerust DJ, Shepherd VL (2007) Virus glycosylation: role in virulence and immune interactions. Trends Microbiol 15(5):211\u2013218","journal-title":"Trends Microbiol"},{"issue":"2","key":"132_CR34","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1128\/JVI.77.2.1337-1346.2003","volume":"77","author":"G Lin","year":"2003","unstructured":"Lin G, Simmons G, Pohlmann S et al (2003) Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J Virol 77(2):1337\u20131346","journal-title":"J Virol"},{"issue":"31","key":"132_CR35","doi-asserted-by":"publisher","first-page":"32035","DOI":"10.1074\/jbc.M402296200","volume":"279","author":"P-Y Lozach","year":"2004","unstructured":"Lozach P-Y, Amara A, Bartosch B et al (2004) C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J Biol Chem 279(31):32035\u201332045","journal-title":"J Biol Chem"},{"issue":"6","key":"132_CR36","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/tra.12393","volume":"17","author":"P Leger","year":"2016","unstructured":"Leger P, Tetard M, Youness B et al (2016) Differential use of the C-type lectins L-SIGN and DC-SIGN for phlebovirus endocytosis. Traffic 17(6):639\u2013656","journal-title":"Traffic"},{"issue":"1","key":"132_CR37","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.chom.2011.06.007","volume":"10","author":"PY Lozach","year":"2011","unstructured":"Lozach PY, Kuhbacher A, Meier R et al (2011) DC-SIGN as a receptor for phleboviruses. Cell Host Microbe 10(1):75\u201388","journal-title":"Cell Host Microbe"},{"issue":"3","key":"132_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/v9030059","volume":"9","author":"J Monteiro","year":"2017","unstructured":"Monteiro J, Lepenies B (2017) Myeloid C-type lectin receptors in viral recognition and antiviral immunity. Viruses 9(3):59","journal-title":"Viruses"},{"issue":"26","key":"132_CR39","doi-asserted-by":"publisher","first-page":"6123","DOI":"10.1016\/j.febslet.2006.10.009","volume":"580","author":"E van Liempt","year":"2006","unstructured":"van Liempt E, Bank CM, Mehta P et al (2006) Specificity of DC-SIGN for mannose- and fucose-containing glycans. FEBS Lett 580(26):6123\u20136131","journal-title":"FEBS Lett"},{"issue":"31","key":"132_CR40","doi-asserted-by":"publisher","first-page":"28939","DOI":"10.1074\/jbc.M104565200","volume":"276","author":"DA Mitchell","year":"2001","unstructured":"Mitchell DA, Fadden AJ, Drickamer K (2001) A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. J Biol Chem 276(31):28939\u201328945","journal-title":"J Biol Chem"},{"issue":"17","key":"132_CR41","doi-asserted-by":"publisher","first-page":"8356","DOI":"10.1073\/pnas.89.17.8356","volume":"89","author":"BM Curtis","year":"1992","unstructured":"Curtis BM, Scharnowske S, Watson AJ (1992) Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120. Proc Natl Acad Sci U S A 89(17):8356\u20138360","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"132_CR42","doi-asserted-by":"publisher","first-page":"6841","DOI":"10.1128\/JVI.76.13.6841-6844.2002","volume":"76","author":"CP Alvarez","year":"2002","unstructured":"Alvarez CP, Lasala F, Carrillo J et al (2002) C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans. J Virol 76(13):6841\u20136844","journal-title":"J Virol"},{"issue":"1","key":"132_CR43","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1006\/viro.2002.1730","volume":"305","author":"G Simmons","year":"2003","unstructured":"Simmons G, Reeves JD, Grogan CC et al (2003) DC-SIGN and DC-SIGNR bind Ebola glycoproteins and enhance infection of macrophages and endothelial cells. Virology 305(1):115\u2013123","journal-title":"Virology"},{"issue":"5","key":"132_CR44","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/S0092-8674(00)80693-5","volume":"100","author":"TBH Geijtenbeek","year":"2000","unstructured":"Geijtenbeek TBH, Torensma R, Van Vliet SJ et al (2000) Identification of DC-SIGN, a novel dendritic cell\u2013specific ICAM-3 receptor that supports primary immune responses. Cell 100(5):575\u2013585","journal-title":"Cell"},{"issue":"24","key":"132_CR45","doi-asserted-by":"publisher","first-page":"12855","DOI":"10.1128\/JVI.76.24.12855-12865.2002","volume":"76","author":"PW Hong","year":"2002","unstructured":"Hong PW, Flummerfelt KB, de Parseval A et al (2002) Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: implications for structural analyses of gp120-DC-SIGN binding. J Virol 76(24):12855\u201312865","journal-title":"J Virol"},{"issue":"2","key":"132_CR46","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/immu.200310024","volume":"33","author":"DG Nguyen","year":"2003","unstructured":"Nguyen DG, Hildreth JEK (2003) Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. Eur J Immunol 33(2):483\u2013493","journal-title":"Eur J Immunol"},{"issue":"17","key":"132_CR47","doi-asserted-by":"publisher","first-page":"11027","DOI":"10.1074\/jbc.M809698200","volume":"284","author":"J Lai","year":"2009","unstructured":"Lai J, Bernhard OK, Turville SG et al (2009) Oligomerization of the macrophage mannose receptor enhances gp120-mediated binding of HIV-1. J Biol Chem 284(17):11027\u201311038","journal-title":"J Biol Chem"},{"issue":"2","key":"132_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0040017","volume":"4","author":"JL Miller","year":"2008","unstructured":"Miller JL, Dewet BJM, Martinez-Pomares L et al (2008) The mannose receptor mediates dengue virus infection of macrophages. PLoS Pathog 4(2):e17","journal-title":"PLoS Pathog"},{"issue":"35","key":"132_CR49","doi-asserted-by":"publisher","first-page":"21473","DOI":"10.1074\/jbc.M115.637363","volume":"290","author":"N Altg\u00e4rde","year":"2015","unstructured":"Altg\u00e4rde N, Eriksson C, Peerboom N et al (2015) Mucin-like region of herpes simplex virus type 1 attachment protein glycoprotein C (gC) modulates the virus-glycosaminoglycan interaction. J Biol Chem 290(35):21473\u201321485","journal-title":"J Biol Chem"},{"issue":"2","key":"132_CR50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005445","volume":"12","author":"JA Stone","year":"2016","unstructured":"Stone JA, Nicola AV, Baum LG et al (2016) Multiple novel functions of henipavirus O-glycans: the first O-glycan functions identified in the paramyxovirus family. PLoS Pathog 12(2):e1005445","journal-title":"PLoS Pathog"},{"key":"132_CR51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.virol.2015.04.005","volume":"483","author":"S Luo","year":"2015","unstructured":"Luo S, Hu K, He S et al (2015) Contribution of N-linked glycans on HSV-2 gB to cell\u2013cell fusion and viral entry. Virology 483:72\u201382","journal-title":"Virology"},{"issue":"24","key":"132_CR52","doi-asserted-by":"publisher","first-page":"12850","DOI":"10.1128\/JVI.01499-10","volume":"84","author":"K Ito","year":"2010","unstructured":"Ito K, Qin Y, Guarnieri M et al (2010) Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site. J Virol 84(24):12850\u201312861","journal-title":"J Virol"},{"issue":"10","key":"132_CR53","doi-asserted-by":"publisher","first-page":"5762","DOI":"10.1073\/pnas.95.10.5762","volume":"95","author":"VE Volchkov","year":"1998","unstructured":"Volchkov VE, Feldmann H, Volchkova VA et al (1998) Processing of the Ebola virus glycoprotein by the proprotein convertase furin. Proc Natl Acad Sci U S A 95(10):5762\u20135767","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"132_CR54","doi-asserted-by":"publisher","first-page":"5860","DOI":"10.1074\/jbc.M116.768168","volume":"292","author":"B Wang","year":"2017","unstructured":"Wang B, Wang Y, Frabutt DA et al (2017) Mechanistic understanding of N-glycosylation in Ebola virus glycoprotein maturation and function. J Biol Chem 292(14):5860\u20135870","journal-title":"J Biol Chem"},{"issue":"11","key":"132_CR55","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/nsmb1161","volume":"13","author":"G Szakonyi","year":"2006","unstructured":"Szakonyi G, Klein MG, Hannan JP et al (2006) Structure of the Epstein-Barr virus major envelope glycoprotein. Nat Struct Mol Biol 13(11):996\u20131001","journal-title":"Nat Struct Mol Biol"},{"issue":"11","key":"132_CR56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005276","volume":"11","author":"R Sommerstein","year":"2015","unstructured":"Sommerstein R, Flatz L, Remy MM et al (2015) Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection. PLoS Pathog 11(11):e1005276","journal-title":"PLoS Pathog"},{"issue":"15","key":"132_CR57","doi-asserted-by":"publisher","first-page":"8072","DOI":"10.1128\/JVI.00459-07","volume":"81","author":"E Falkowska","year":"2007","unstructured":"Falkowska E, Kajumo F, Garcia E et al (2007) Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J Virol 81(15):8072\u20138079","journal-title":"J Virol"},{"key":"132_CR58","doi-asserted-by":"publisher","first-page":"46374","DOI":"10.1038\/srep46374","volume":"7","author":"DR Beniac","year":"2017","unstructured":"Beniac DR, Booth TF (2017) Structure of the Ebola virus glycoprotein spike within the virion envelope at 11\u2009\u00c5 resolution. Sci Rep 7:46374","journal-title":"Sci Rep"},{"issue":"12","key":"132_CR59","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/j.jmb.2019.04.016","volume":"431","author":"GE Seabright","year":"2019","unstructured":"Seabright GE, Doores KJ, Burton DR et al (2019) Protein and glycan mimicry in HIV vaccine design. J Mol Biol 431(12):2223\u20132247","journal-title":"J Mol Biol"},{"issue":"6402","key":"132_CR60","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/360358a0","volume":"360","author":"S Hallenberger","year":"1992","unstructured":"Hallenberger S, Bosch V, Angliker H et al (1992) Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 360(6402):358\u2013361","journal-title":"Nature"},{"issue":"6","key":"132_CR61","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1016\/j.celrep.2020.01.056","volume":"30","author":"ZA Silver","year":"2020","unstructured":"Silver ZA, Antonopoulos A, Haslam SM et al (2020) Discovery of O-linked carbohydrate on HIV-1 envelope and its role in shielding against one category of broadly neutralizing antibodies. Cell Rep 30(6):1862\u20131869.e1864","journal-title":"Cell Rep"},{"issue":"4760","key":"132_CR62","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1126\/science.3014647","volume":"233","author":"LA Lasky","year":"1986","unstructured":"Lasky LA, Groopman JE, Fennie CW et al (1986) Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 233(4760):209\u2013212","journal-title":"Science"},{"issue":"6277","key":"132_CR63","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1126\/science.aad2450","volume":"351","author":"JH Lee","year":"2016","unstructured":"Lee JH, Ozorowski G, Ward AB (2016) Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 351(6277):1043\u20131048","journal-title":"Science"},{"issue":"4","key":"132_CR64","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.cell.2016.04.010","volume":"165","author":"GB Stewart-Jones","year":"2016","unstructured":"Stewart-Jones GB, Soto C, Lemmin T et al (2016) Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G. Cell 165(4):813\u2013826","journal-title":"Cell"},{"issue":"6929","key":"132_CR65","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nature01470","volume":"422","author":"X Wei","year":"2003","unstructured":"Wei X, Decker JM, Wang S et al (2003) Antibody neutralization and escape by HIV-1. Nature 422(6929):307\u2013312","journal-title":"Nature"},{"issue":"11","key":"132_CR66","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1038\/nm.2985","volume":"18","author":"PL Moore","year":"2012","unstructured":"Moore PL, Gray ES, Wibmer CK et al (2012) Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 18(11):1688\u20131692","journal-title":"Nat Med"},{"issue":"22","key":"132_CR67","doi-asserted-by":"publisher","first-page":"12625","DOI":"10.1128\/JVI.78.22.12625-12637.2004","volume":"78","author":"L Dacheux","year":"2004","unstructured":"Dacheux L, Moreau A, Ataman-Onal Y et al (2004) Evolutionary dynamics of the glycan shield of the human immunodeficiency virus envelope during natural infection and implications for exposure of the 2G12 epitope. J Virol 78(22):12625\u201312637","journal-title":"J Virol"},{"issue":"4","key":"132_CR68","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.celrep.2018.09.087","volume":"25","author":"K Wagh","year":"2018","unstructured":"Wagh K, Kreider EF, Li Y et al (2018) Completeness of HIV-1 envelope glycan shield at transmission determines neutralization breadth. Cell Rep 25(4):893\u2013908.e897","journal-title":"Cell Rep"},{"issue":"7","key":"132_CR69","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1128\/JVI.78.7.3279-3295.2004","volume":"78","author":"RA McCaffrey","year":"2004","unstructured":"McCaffrey RA, Saunders C, Hensel M et al (2004) N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J Virol 78(7):3279\u20133295","journal-title":"J Virol"},{"issue":"2","key":"132_CR70","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0042-6822(03)00294-0","volume":"313","author":"M Koch","year":"2003","unstructured":"Koch M, Pancera M, Kwong PD et al (2003) Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313(2):387\u2013400","journal-title":"Virology"},{"issue":"2","key":"132_CR71","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1128\/JVI.01691-07","volume":"82","author":"Y Li","year":"2008","unstructured":"Li Y, Cleveland B, Klots I et al (2008) Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 82(2):638\u2013651","journal-title":"J Virol"},{"issue":"2","key":"132_CR72","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1006\/viro.1994.1141","volume":"199","author":"NK Back","year":"1994","unstructured":"Back NK, Smit L, De Jong JJ et al (1994) An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 199(2):431\u2013438","journal-title":"Virology"},{"issue":"8","key":"132_CR73","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1128\/JVI.03608-14","volume":"89","author":"RM Lynch","year":"2015","unstructured":"Lynch RM, Wong P, Tran L et al (2015) HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J Virol 89(8):4201\u20134213","journal-title":"J Virol"},{"issue":"10","key":"132_CR74","doi-asserted-by":"publisher","first-page":"4878","DOI":"10.1128\/JVI.80.10.4878-4889.2006","volume":"80","author":"HC Aguilar","year":"2006","unstructured":"Aguilar HC, Matreyek KA, Filone CM et al (2006) N-Glycans on Nipah virus fusion protein protect against neutralization but reduce membrane fusion and viral entry. J Virol 80(10):4878\u20134889","journal-title":"J Virol"},{"issue":"16","key":"132_CR75","doi-asserted-by":"publisher","first-page":"9049","DOI":"10.1128\/JVI.01161-14","volume":"88","author":"R Julithe","year":"2014","unstructured":"Julithe R, Abou-Jaoude G, Sureau C (2014) Modification of the hepatitis B virus envelope protein glycosylation pattern interferes with secretion of viral particles, infectivity, and susceptibility to neutralizing antibodies. J Virol 88(16):9049\u20139059","journal-title":"J Virol"},{"issue":"1","key":"132_CR76","doi-asserted-by":"publisher","first-page":"e00862","DOI":"10.1128\/mBio.00862-13","volume":"5","author":"NJ Lennemann","year":"2014","unstructured":"Lennemann NJ, Rhein BA, Ndungo E et al (2014) Comprehensive functional analysis of N-linked glycans on Ebola virus GP1. mBio 5(1):e00862\u2013e00813","journal-title":"mBio"},{"issue":"12","key":"132_CR77","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1128\/jvi.63.12.5184-5193.1989","volume":"63","author":"DL Sodora","year":"1989","unstructured":"Sodora DL, Cohen GH, Eisenberg RJ (1989) Influence of asparagine-linked oligosaccharides on antigenicity, processing, and cell surface expression of herpes simplex virus type 1 glycoprotein D. J Virol 63(12):5184\u20135193","journal-title":"J Virol"},{"issue":"2","key":"132_CR78","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/0042-6822(91)90915-X","volume":"181","author":"TC Hobman","year":"1991","unstructured":"Hobman TC, Qiu ZY, Chaye H et al (1991) Analysis of rubella virus E1 glycosylation mutants expressed in COS cells. Virology 181(2):768\u2013772","journal-title":"Virology"},{"issue":"24","key":"132_CR79","doi-asserted-by":"publisher","first-page":"12088","DOI":"10.1128\/JVI.75.24.12088-12097.2001","volume":"75","author":"A Fournillier","year":"2001","unstructured":"Fournillier A, Wychowski C, Boucreux D et al (2001) Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites. J Virol 75(24):12088\u201312097","journal-title":"J Virol"},{"issue":"22","key":"132_CR80","doi-asserted-by":"publisher","first-page":"11905","DOI":"10.1128\/JVI.01548-10","volume":"84","author":"F Helle","year":"2010","unstructured":"Helle F, Vieyres G, Elkrief L et al (2010) Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol 84(22):11905\u201311915","journal-title":"J Virol"},{"issue":"36","key":"132_CR81","doi-asserted-by":"publisher","first-page":"6572","DOI":"10.1016\/j.vaccine.2007.07.003","volume":"25","author":"M Liu","year":"2007","unstructured":"Liu M, Chen H, Luo F et al (2007) Deletion of N-glycosylation sites of hepatitis C virus envelope protein E1 enhances specific cellular and humoral immune responses. Vaccine 25(36):6572\u20136580","journal-title":"Vaccine"},{"issue":"1","key":"132_CR82","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1084\/jem.182.1.185","volume":"182","author":"QJ Sattentau","year":"1995","unstructured":"Sattentau QJ, Moore JP (1995) Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer. J Exp Med 182(1):185\u2013196","journal-title":"J Exp Med"},{"issue":"9","key":"132_CR83","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003618","volume":"9","author":"RW Sanders","year":"2013","unstructured":"Sanders RW, Derking R, Cupo A et al (2013) A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 9(9):e1003618","journal-title":"PLoS Pathog"},{"issue":"12","key":"132_CR84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003065","volume":"8","author":"GS Mohan","year":"2012","unstructured":"Mohan GS, Li W, Ye L et al (2012) Antigenic subversion: a novel mechanism of host immune evasion by Ebola virus. PLoS Pathog 8(12):e1003065","journal-title":"PLoS Pathog"},{"issue":"5","key":"132_CR85","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1128\/JVI.80.5.2515-2528.2006","volume":"80","author":"PL Moore","year":"2006","unstructured":"Moore PL, Crooks ET, Porter L et al (2006) Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 80(5):2515\u20132528","journal-title":"J Virol"},{"issue":"12","key":"132_CR86","doi-asserted-by":"publisher","first-page":"6739","DOI":"10.3390\/v7122969","volume":"7","author":"JC Trefry","year":"2015","unstructured":"Trefry JC, Wollen SE, Nasar F et al (2015) Ebola virus infections in nonhuman primates are temporally influenced by glycoprotein poly-U editing site populations in the exposure material. Viruses 7(12):6739\u20136754","journal-title":"Viruses"},{"issue":"s1","key":"132_CR87","doi-asserted-by":"publisher","first-page":"S235","DOI":"10.1086\/514280","volume":"179","author":"T Maruyama","year":"1999","unstructured":"Maruyama T, Parren PW, Sanchez A et al (1999) Recombinant human monoclonal antibodies to Ebola virus. J Infect Dis 179(s1):S235\u2013S239","journal-title":"J Infect Dis"},{"issue":"10","key":"132_CR88","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1007\/s00251-005-0047-4","volume":"57","author":"C Druar","year":"2005","unstructured":"Druar C, Saini SS, Cossitt MA et al (2005) Analysis of the expressed heavy chain variable-region genes of Macaca fascicularis and isolation of monoclonal antibodies specific for the Ebola virus\u2019 soluble glycoprotein. Immunogenetics 57(10):730\u2013738","journal-title":"Immunogenetics"},{"issue":"5","key":"132_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003258","volume":"9","author":"JD Cook","year":"2013","unstructured":"Cook JD, Lee JE (2013) The secret life of viral entry glycoproteins: moonlighting in immune evasion. PLoS Pathog 9(5):e1003258","journal-title":"PLoS Pathog"},{"key":"132_CR90","unstructured":"WHO (2019) Ten threats to global health in 2019. https:\/\/www.who.int\/news-room\/feature-stories\/ten-threats-to-global-health-in-2019. Accessed 20 Apr 2020"},{"issue":"5","key":"132_CR91","doi-asserted-by":"publisher","first-page":"264","DOI":"10.3855\/jidc.1204","volume":"4","author":"E Tognotti","year":"2010","unstructured":"Tognotti E (2010) The eradication of smallpox, a success story for modern medicine and public health: what lessons for the future? J Infect Dev Ctries 4(5):264\u2013266","journal-title":"J Infect Dev Ctries"},{"issue":"6","key":"132_CR92","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/emmm.201403876","volume":"6","author":"I Delany","year":"2014","unstructured":"Delany I, Rappuoli R, De Gregorio E (2014) Vaccines for the 21st century. EMBO Mol Med 6(6):708\u2013720","journal-title":"EMBO Mol Med"},{"issue":"2","key":"132_CR93","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1080\/07853890.2017.1407035","volume":"50","author":"V Vetter","year":"2018","unstructured":"Vetter V, Denizer G, Friedland LR et al (2018) Understanding modern-day vaccines: what you need to know. Ann Med 50(2):110\u2013120","journal-title":"Ann Med"},{"issue":"4","key":"132_CR94","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1093\/infdis\/jir327","volume":"204","author":"DM Morens","year":"2011","unstructured":"Morens DM, Holmes EC, Davis AS et al (2011) Global rinderpest eradication: lessons learned and why humans should celebrate too. J Infect Dis 204(4):502\u2013505","journal-title":"J Infect Dis"},{"issue":"2","key":"132_CR95","doi-asserted-by":"publisher","first-page":"579","DOI":"10.20506\/rst.36.2.2676","volume":"36","author":"K Hamilton","year":"2017","unstructured":"Hamilton K, Baron MD, Matsuo K et al (2017) Rinderpest eradication: challenges for remaining disease free and implications for future eradication efforts. Rev Sci Tech 36(2):579\u2013588","journal-title":"Rev Sci Tech"},{"key":"132_CR96","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.virol.2015.03.032","volume":"479-480","author":"PD Minor","year":"2015","unstructured":"Minor PD (2015) Live attenuated vaccines: historical successes and current challenges. Virology 479-480:379\u2013392","journal-title":"Virology"},{"issue":"34","key":"132_CR97","doi-asserted-by":"publisher","first-page":"12283","DOI":"10.1073\/pnas.1400472111","volume":"111","author":"S Plotkin","year":"2014","unstructured":"Plotkin S (2014) History of vaccination. Proc Natl Acad Sci U S A 111(34):12283\u201312287","journal-title":"Proc Natl Acad Sci U S A"},{"key":"132_CR98","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3389\/fpubh.2015.00269","volume":"3","author":"I Hajj Hussein","year":"2015","unstructured":"Hajj Hussein I, Chams N, Chams S et al (2015) Vaccines through centuries: major cornerstones of global health. Front Public Health 3:269","journal-title":"Front Public Health"},{"issue":"44","key":"132_CR99","doi-asserted-by":"publisher","first-page":"5951","DOI":"10.1016\/j.vaccine.2017.03.032","volume":"35","author":"ADT Barrett","year":"2017","unstructured":"Barrett ADT (2017) Yellow fever live attenuated vaccine: a very successful live attenuated vaccine but still we have problems controlling the disease. Vaccine 35(44):5951\u20135955","journal-title":"Vaccine"},{"issue":"10","key":"132_CR100","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","volume":"66","author":"H Caplen","year":"1985","unstructured":"Caplen H, Peters CJ, Bishop DH (1985) Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 66(10):2271\u20132277","journal-title":"J Gen Virol"},{"issue":"24","key":"132_CR101","doi-asserted-by":"publisher","first-page":"13566","DOI":"10.1128\/JVI.02081-12","volume":"86","author":"N Lokugamage","year":"2012","unstructured":"Lokugamage N, Freiberg AN, Morrill JC et al (2012) Genetic subpopulations of Rift Valley fever virus strains ZH548 and MP-12 and recombinant MP-12 strains. J Virol 86(24):13566\u201313575","journal-title":"J Virol"},{"issue":"14","key":"132_CR102","doi-asserted-by":"publisher","first-page":"7262","DOI":"10.1128\/JVI.00135-15","volume":"89","author":"T Ikegami","year":"2015","unstructured":"Ikegami T, Hill TE, Smith JK et al (2015) Rift Valley fever virus MP-12 vaccine is fully attenuated by a combination of partial attenuations in the S, M, and L segments. J Virol 89(14):7262\u20137276","journal-title":"J Virol"},{"issue":"7","key":"132_CR103","first-page":"1042","volume":"48","author":"JC Morrill","year":"1987","unstructured":"Morrill JC, Jennings GB, Caplen H et al (1987) Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes. Am J Vet Res 48(7):1042\u20131047","journal-title":"Am J Vet Res"},{"issue":"21\u201322","key":"132_CR104","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1016\/S0264-410X(03)00131-2","volume":"21","author":"JC Morrill","year":"2003","unstructured":"Morrill JC, Peters CJ (2003) Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys. Vaccine 21(21\u201322):2994\u20133002","journal-title":"Vaccine"},{"issue":"10","key":"132_CR105","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2460\/ajvr.1997.58.10.1104","volume":"58","author":"JC Morrill","year":"1997","unstructured":"Morrill JC, Mebus CA, Peters CJ (1997) Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res 58(10):1104\u20131109","journal-title":"Am J Vet Res"},{"key":"132_CR106","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.vetmic.2019.01.027","volume":"230","author":"Y Lang","year":"2019","unstructured":"Lang Y, Li Y, Jasperson D et al (2019) Identification and evaluation of antivirals for Rift Valley fever virus. Vet Microbiol 230:110\u2013116","journal-title":"Vet Microbiol"},{"issue":"12","key":"132_CR107","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/14712598.2019.1662784","volume":"19","author":"T Ikegami","year":"2019","unstructured":"Ikegami T (2019) Candidate vaccines for human Rift Valley fever. Expert Opin Biol Ther 19(12):1333\u20131342","journal-title":"Expert Opin Biol Ther"},{"issue":"4","key":"132_CR108","doi-asserted-by":"publisher","first-page":"604","DOI":"10.3181\/00379727-33-8467P","volume":"33","author":"F Thomas Jr","year":"1936","unstructured":"Thomas Jr F, Magill T (1936) Vaccination of human subjects with virus of human influenza. Proc Soc Exp Biol Med 33(4):604\u2013606","journal-title":"Proc Soc Exp Biol Med"},{"issue":"5","key":"132_CR109","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2105\/AJPH.44.5.563","volume":"44","author":"JE Salk","year":"1954","unstructured":"Salk JE, Krech U, Youngner JS et al (1954) Formaldehyde treatment and safety testing of experimental poliomyelitis vaccines. Am J Public Health Nations Health 44(5):563\u2013570","journal-title":"Am J Public Health Nations Health"},{"issue":"1","key":"132_CR110","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/jmv.1890190105","volume":"19","author":"PJ Provost","year":"1986","unstructured":"Provost PJ, Hughes JV, Miller WJ et al (1986) An inactivated hepatitis A viral vaccine of cell culture origin. J Med Virol 19(1):23\u201331","journal-title":"J Med Virol"},{"key":"132_CR111","first-page":"1806","volume":"28","author":"C Kunz","year":"1962","unstructured":"Kunz C (1962) Aktiv und passive Immunoprophylaxe der Fruhsommer-Meningoencephalitis (FSME). Arzneimittelforschung 28:1806","journal-title":"Arzneimittelforschung"},{"issue":"1","key":"132_CR112","first-page":"25","volume":"13","author":"T Yamashita","year":"1970","unstructured":"Yamashita T, Ishikawa N, Hojo F et al (1970) Japanese encephalitis purified vaccine. II. Purity of the mouse brain vaccine purified by ultracentrifugation. Biken J 13(1):25\u201338","journal-title":"Biken J"},{"issue":"10","key":"132_CR113","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004167","volume":"9","author":"YC Fan","year":"2015","unstructured":"Fan YC, Chiu HC, Chen LK et al (2015) Formalin inactivation of Japanese encephalitis virus vaccine alters the antigenicity and immunogenicity of a neutralization epitope in envelope protein domain III. PLoS Negl Trop Dis 9(10):e0004167","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"132_CR114","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1128\/iai.62.5.1830-1834.1994","volume":"62","author":"A di Tommaso","year":"1994","unstructured":"di Tommaso A, de Magistris MT, Bugnoli M et al (1994) Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing. Infect Immun 62(5):1830\u20131834","journal-title":"Infect Immun"},{"issue":"5","key":"132_CR115","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/0264-410X(95)00230-X","volume":"14","author":"PH Ibsen","year":"1996","unstructured":"Ibsen PH (1996) The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies. Vaccine 14(5):359\u2013368","journal-title":"Vaccine"},{"issue":"13","key":"132_CR116","doi-asserted-by":"publisher","first-page":"5965","DOI":"10.1128\/JVI.00235-16","volume":"90","author":"I Widjaja","year":"2016","unstructured":"Widjaja I, Wicht O, Luytjes W et al (2016) Characterization of epitope-specific anti-respiratory syncytial virus (anti-RSV) antibody responses after natural infection and after vaccination with formalin-inactivated RSV. J Virol 90(13):5965\u20135977","journal-title":"J Virol"},{"key":"132_CR117","first-page":"153","volume":"121","author":"TG Clark","year":"2005","unstructured":"Clark TG, Cassidy-Hanley D (2005) Recombinant subunit vaccines: potentials and constraints. Dev Biol (Basel) 121:153\u2013163","journal-title":"Dev Biol (Basel)"},{"issue":"4","key":"132_CR118","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.patbio.2010.01.006","volume":"58","author":"ML Michel","year":"2010","unstructured":"Michel ML, Tiollais P (2010) Hepatitis B vaccines: protective efficacy and therapeutic potential. Pathol Biol (Paris) 58(4):288\u2013295","journal-title":"Pathol Biol (Paris)"},{"key":"132_CR119","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ejpb.2015.05.023","volume":"94","author":"PC Soema","year":"2015","unstructured":"Soema PC, Kompier R, Amorij J-P et al (2015) Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm 94:251\u2013263","journal-title":"Eur J Pharm Biopharm"},{"issue":"34","key":"132_CR120","doi-asserted-by":"publisher","first-page":"12288","DOI":"10.1073\/pnas.1402981111","volume":"111","author":"R Rappuoli","year":"2014","unstructured":"Rappuoli R, Pizza M, Del Giudice G et al (2014) Vaccines, new opportunities for a new society. Proc Natl Acad Sci U S A 111(34):12288\u201312293","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"132_CR121","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/glycob\/cwr180","volume":"22","author":"ML Colgrave","year":"2012","unstructured":"Colgrave ML, Snelling HJ, Shiell BJ et al (2012) Site occupancy and glycan compositional analysis of two soluble recombinant forms of the attachment glycoprotein of Hendra virus. Glycobiology 22(4):572\u2013584","journal-title":"Glycobiology"},{"issue":"2","key":"132_CR122","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/(SICI)1522-2683(19990201)20:2<362::AID-ELPS362>3.0.CO;2-V","volume":"20","author":"TF Orntoft","year":"1999","unstructured":"Orntoft TF, Vestergaard EM (1999) Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis 20(2):362\u2013371","journal-title":"Electrophoresis"},{"issue":"1","key":"132_CR123","first-page":"7","volume":"81","author":"D Rendi\u0107","year":"2008","unstructured":"Rendi\u0107 D, Wilson IB, Paschinger K (2008) The glycosylation capacity of insect cells. Croat Chem Acta 81(1):7\u201321","journal-title":"Croat Chem Acta"},{"issue":"2","key":"132_CR124","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0016682","volume":"6","author":"G Vandenborre","year":"2011","unstructured":"Vandenborre G, Smagghe G, Ghesquiere B et al (2011) Diversity in protein glycosylation among insect species. PLoS One 6(2):e16682","journal-title":"PLoS One"},{"key":"132_CR125","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ibmb.2017.02.005","volume":"83","author":"T Walski","year":"2017","unstructured":"Walski T, De Schutter K, Van Damme EJM et al (2017) Diversity and functions of protein glycosylation in insects. Insect Biochem Mol Biol 83:21\u201334","journal-title":"Insect Biochem Mol Biol"},{"issue":"3","key":"132_CR126","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.cell.2018.01.016","volume":"172","author":"HJ Joshi","year":"2018","unstructured":"Joshi HJ, Narimatsu Y, Schjoldager KT et al (2018) SnapShot: O-glycosylation pathways across kingdoms. Cell 172(3):632\u2013632.e632","journal-title":"Cell"},{"issue":"1","key":"132_CR127","first-page":"112","volume":"19","author":"BD Hill","year":"2018","unstructured":"Hill BD, Zak A, Khera E et al (2018) Engineering virus-like particles for antigen and drug delivery. Curr Protein Pept Sci 19(1):112\u2013127","journal-title":"Curr Protein Pept Sci"},{"issue":"10","key":"132_CR128","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1586\/erv.10.115","volume":"9","author":"A Rold\u00e3o","year":"2010","unstructured":"Rold\u00e3o A, Mellado MCM, Castilho LR et al (2010) Virus-like particles in vaccine development. Expert Rev Vaccines 9(10):1149\u20131176","journal-title":"Expert Rev Vaccines"},{"issue":"14","key":"132_CR129","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1001\/jama.1982.03320390074052","volume":"247","author":"S Krugman","year":"1982","unstructured":"Krugman S (1982) The newly licensed hepatitis B vaccine. Characteristics and indications for use. JAMA 247(14):2012\u20132015","journal-title":"JAMA"},{"issue":"2","key":"132_CR130","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/vaccines3020320","volume":"3","author":"A Pasquale","year":"2015","unstructured":"Pasquale A, Preiss S, Silva F et al (2015) Vaccine adjuvants: from 1920 to 2015 and beyond. Vaccine 3(2):320\u2013343","journal-title":"Vaccine"},{"issue":"7","key":"132_CR131","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1099\/jmm.0.038943-0","volume":"61","author":"M Kool","year":"2012","unstructured":"Kool M, Fierens K, Lambrecht BN (2012) Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol 61(7):927\u2013934","journal-title":"J Med Microbiol"},{"issue":"10","key":"132_CR132","doi-asserted-by":"publisher","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","volume":"183","author":"AM Didierlaurent","year":"2009","unstructured":"Didierlaurent AM, Morel S, Lockman L et al (2009) AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 183(10):6186\u20136197","journal-title":"J Immunol"},{"issue":"13","key":"132_CR133","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/j.vaccine.2011.01.011","volume":"29","author":"S Morel","year":"2011","unstructured":"Morel S, Didierlaurent A, Bourguignon P et al (2011) Adjuvant system AS03 containing \u03b1-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29(13):2461\u20132473","journal-title":"Vaccine"},{"issue":"23","key":"132_CR134","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1016\/j.vaccine.2019.04.048","volume":"37","author":"C Cohet","year":"2019","unstructured":"Cohet C, van der Most R, Bauchau V et al (2019) Safety of AS03-adjuvanted influenza vaccines: a review of the evidence. Vaccine 37(23):3006\u20133021","journal-title":"Vaccine"},{"key":"132_CR135","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.biopha.2018.06.026","volume":"105","author":"A Batista-Duharte","year":"2018","unstructured":"Batista-Duharte A, Mart\u00ednez DT, Carlos IZ (2018) Efficacy and safety of immunological adjuvants. Where is the cut-off? Biomed Pharmacother 105:616\u2013624","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"132_CR136","doi-asserted-by":"publisher","first-page":"7639","DOI":"10.1073\/pnas.78.12.7639","volume":"78","author":"GM Air","year":"1981","unstructured":"Air GM (1981) Sequence relationships among the hemagglutinin genes of 12 subtypes of influenza A virus. Proc Natl Acad Sci U S A 78(12):7639\u20137643","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"132_CR137","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.tim.2014.01.010","volume":"22","author":"Y Wu","year":"2014","unstructured":"Wu Y, Wu Y, Tefsen B et al (2014) Bat-derived influenza-like viruses H17N10 and H18N11. Trends Microbiol 22(4):183\u2013191","journal-title":"Trends Microbiol"},{"issue":"1","key":"132_CR138","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12985-017-0918-y","volume":"15","author":"GA Sautto","year":"2018","unstructured":"Sautto GA, Kirchenbaum GA, Ross TM (2018) Towards a universal influenza vaccine: different approaches for one goal. Virol J 15(1):17","journal-title":"Virol J"},{"key":"132_CR139","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.coviro.2014.06.004","volume":"7","author":"GM Air","year":"2014","unstructured":"Air GM (2014) Influenza virus\u2013glycan interactions. Curr Opin Virol 7:128\u2013133","journal-title":"Curr Opin Virol"},{"issue":"12","key":"132_CR140","doi-asserted-by":"crossref","first-page":"5484","DOI":"10.4049\/jimmunol.150.12.5484","volume":"150","author":"SL Epstein","year":"1993","unstructured":"Epstein SL, Misplon JA, Lawson CM et al (1993) Beta 2-microglobulin-deficient mice can be protected against influenza A infection by vaccination with vaccinia-influenza recombinants expressing hemagglutinin and neuraminidase. J Immunol 150(12):5484\u20135493","journal-title":"J Immunol"},{"issue":"4","key":"132_CR141","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/ni.3680","volume":"18","author":"D Angeletti","year":"2017","unstructured":"Angeletti D, Gibbs JS, Angel M et al (2017) Defining B cell immunodominance to viruses. Nat Immunol 18(4):456\u2013463","journal-title":"Nat Immunol"},{"issue":"25","key":"132_CR142","doi-asserted-by":"publisher","first-page":"18283","DOI":"10.1074\/jbc.M113.468884","volume":"288","author":"TM Doyle","year":"2013","unstructured":"Doyle TM, Jaentschke B, Van Domselaar G et al (2013) The universal epitope of influenza A viral neuraminidase fundamentally contributes to enzyme activity and viral replication. J Biol Chem 288(25):18283\u201318289","journal-title":"J Biol Chem"},{"issue":"1","key":"132_CR143","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/nyas.12462","volume":"1323","author":"RG Webster","year":"2014","unstructured":"Webster RG, Govorkova EA (2014) Continuing challenges in influenza. Ann N Y Acad Sci 1323(1):115\u2013139","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"132_CR144","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/infdis\/jiy103","volume":"218","author":"EJ Erbelding","year":"2018","unstructured":"Erbelding EJ, Post DJ, Stemmy EJ et al (2018) A universal influenza vaccine: the strategic plan for the National Institute of allergy and infectious diseases. J Infect Dis 218(3):347\u2013354","journal-title":"J Infect Dis"},{"issue":"4","key":"132_CR145","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41573-019-0056-x","volume":"19","author":"CJ Wei","year":"2020","unstructured":"Wei CJ, Crank MC, Shiver J et al (2020) Next-generation influenza vaccines: opportunities and challenges. Nat Rev Drug Discov 19(4):239\u2013252","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"132_CR146","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.chom.2015.02.001","volume":"17","author":"I Wendel","year":"2015","unstructured":"Wendel I, Matrosovich M, Klenk HD (2015) SnapShot: evolution of human influenza A viruses. Cell Host Microbe 17(3):416\u2013416.e411","journal-title":"Cell Host Microbe"},{"key":"132_CR147","unstructured":"WHO (2020) Influenza (seasonal) fact sheet. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/influenza-(seasonal). Accessed 18 Apr 2020"},{"issue":"12","key":"132_CR148","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1074\/mcp.R119.001491","volume":"18","author":"D Chang","year":"2019","unstructured":"Chang D, Zaia J (2019) Why glycosylation matters in building a better flu vaccine. Mol Cell Proteomics 18(12):2348\u20132358","journal-title":"Mol Cell Proteomics"},{"issue":"32","key":"132_CR149","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1016\/j.vaccine.2009.04.076","volume":"27","author":"J Schwarzer","year":"2009","unstructured":"Schwarzer J, Rapp E, Hennig R et al (2009) Glycan analysis in cell culture-based influenza vaccine production: influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin. Vaccine 27(32):4325\u20134336","journal-title":"Vaccine"},{"issue":"5919","key":"132_CR150","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/303706a0","volume":"303","author":"GC Schild","year":"1983","unstructured":"Schild GC, Oxford JS, de Jong JC et al (1983) Evidence for host-cell selection of influenza virus antigenic variants. Nature 303(5919):706\u2013709","journal-title":"Nature"},{"issue":"1","key":"132_CR151","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/0042-6822(87)90040-7","volume":"160","author":"JS Robertson","year":"1987","unstructured":"Robertson JS, Bootman JS, Newman R et al (1987) Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A (H1N1) virus. Virology 160(1):31\u201337","journal-title":"Virology"},{"issue":"21","key":"132_CR152","doi-asserted-by":"publisher","first-page":"11735","DOI":"10.1128\/JVI.01084-12","volume":"86","author":"RP de Vries","year":"2012","unstructured":"de Vries RP, Smit CH, de Bruin E et al (2012) Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin. J Virol 86(21):11735\u201311744","journal-title":"J Virol"},{"issue":"2","key":"132_CR153","doi-asserted-by":"publisher","first-page":"e01693","DOI":"10.1128\/JVI.01693-18","volume":"93","author":"Y An","year":"2019","unstructured":"An Y, Parsons LM, Jankowska E et al (2019) N-glycosylation of seasonal influenza vaccine hemagglutinins: implication for potency testing and immune processing. J Virol 93(2):e01693\u2013e01618","journal-title":"J Virol"},{"issue":"10","key":"132_CR154","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006682","volume":"13","author":"NC Wu","year":"2017","unstructured":"Wu NC, Zost SJ, Thompson AJ et al (2017) A structural explanation for the low effectiveness of the seasonal influenza H3N2 vaccine. PLoS Pathog 13(10):e1006682","journal-title":"PLoS Pathog"},{"issue":"47","key":"132_CR155","doi-asserted-by":"publisher","first-page":"7019","DOI":"10.1016\/j.vaccine.2019.04.030","volume":"37","author":"G Granicher","year":"2019","unstructured":"Granicher G, Coronel J, Pralow A et al (2019) Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1. Vaccine 37(47):7019\u20137028","journal-title":"Vaccine"},{"issue":"2","key":"132_CR156","doi-asserted-by":"publisher","first-page":"e00204","DOI":"10.1128\/mBio.00204-19","volume":"10","author":"MO Altman","year":"2019","unstructured":"Altman MO, Angel M, Kosik I et al (2019) Human influenza A virus hemagglutinin glycan evolution follows a temporal pattern to a glycan limit. mBio 10(2):e00204\u2013e00219","journal-title":"mBio"},{"issue":"23","key":"132_CR157","doi-asserted-by":"publisher","first-page":"10486","DOI":"10.1128\/JVI.01462-16","volume":"90","author":"D Li","year":"2016","unstructured":"Li D, von Schaewen M, Wang X et al (2016) Altered glycosylation patterns increase immunogenicity of a subunit hepatitis C virus vaccine, inducing neutralizing antibodies which confer protection in mice. J Virol 90(23):10486\u201310498","journal-title":"J Virol"},{"issue":"9","key":"132_CR158","doi-asserted-by":"publisher","first-page":"e02428","DOI":"10.1128\/JVI.02428-16","volume":"91","author":"EP Go","year":"2017","unstructured":"Go EP, Ding H, Zhang S et al (2017) Glycosylation benchmark profile for HIV-1 envelope glycoprotein production based on eleven Env trimers. J Virol 91(9):e02428\u2013e02416","journal-title":"J Virol"},{"issue":"1","key":"132_CR159","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4049\/jimmunol.1201060","volume":"190","author":"J Hutter","year":"2013","unstructured":"Hutter J, Rodig JV, Hoper D et al (2013) Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity. J Immunol 190(1):220\u2013230","journal-title":"J Immunol"},{"issue":"13","key":"132_CR160","doi-asserted-by":"publisher","first-page":"6085","DOI":"10.1128\/JVI.00452-16","volume":"90","author":"WC Liu","year":"2016","unstructured":"Liu WC, Lin YL, Spearman M et al (2016) Influenza virus hemagglutinin glycoproteins with different N-glycan patterns activate dendritic cells in vitro. J Virol 90(13):6085\u20136096","journal-title":"J Virol"},{"issue":"7","key":"132_CR161","doi-asserted-by":"publisher","first-page":"e01403","DOI":"10.1128\/JVI.01403-18","volume":"93","author":"RA Urbanowicz","year":"2019","unstructured":"Urbanowicz RA, Wang R, Schiel JE et al (2019) Antigenicity and immunogenicity of differentially glycosylated hepatitis C virus E2 envelope proteins expressed in mammalian and insect cells. J Virol 93(7):e01403\u2013e01418","journal-title":"J Virol"},{"issue":"8","key":"132_CR162","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1002\/bit.25233","volume":"111","author":"C Ronda","year":"2014","unstructured":"Ronda C, Pedersen LE, Hansen HG et al (2014) Accelerating genome editing in CHO cells using CRISPR Cas9 and CRISPy, a web-based target finding tool. Biotechnol Bioeng 111(8):1604\u20131616","journal-title":"Biotechnol Bioeng"},{"key":"132_CR163","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jbiotec.2014.04.011","volume":"182-183","author":"AM Toth","year":"2014","unstructured":"Toth AM, Kuo C-W, Khoo K-H et al (2014) A new insect cell glycoengineering approach provides baculovirus-inducible glycogene expression and increases human-type glycosylation efficiency. J Biotechnol 182-183:19\u201329","journal-title":"J Biotechnol"},{"key":"132_CR164","doi-asserted-by":"publisher","DOI":"10.1007\/1010_2017_1057","volume-title":"Advances in biochemical engineering\/biotechnology","author":"KM Heffner","year":"2018","unstructured":"Heffner KM, Wang Q, Hizal DB et al (2018) Glycoengineering of mammalian expression systems on a cellular level. In: Advances in biochemical engineering\/biotechnology. Springer, Berlin. https:\/\/doi.org\/10.1007\/1010_2017_1057"},{"issue":"34","key":"132_CR165","doi-asserted-by":"publisher","first-page":"9068","DOI":"10.1073\/pnas.1705836114","volume":"114","author":"H Mabashi-Asazuma","year":"2017","unstructured":"Mabashi-Asazuma H, Jarvis DL (2017) CRISPR-Cas9 vectors for genome editing and host engineering in the baculovirus-insect cell system. Proc Natl Acad Sci U S A 114(34):9068\u20139073","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"132_CR166","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.molcel.2019.05.017","volume":"75","author":"Y Narimatsu","year":"2019","unstructured":"Narimatsu Y, Joshi HJ, Nason R et al (2019) An atlas of human glycosylation pathways enables display of the human glycome by gene engineered cells. Mol Cell 75(2):394\u2013407.e395","journal-title":"Mol Cell"},{"key":"132_CR167","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/nbt.3280","volume":"33","author":"Z Yang","year":"2015","unstructured":"Yang Z, Wang S, Halim A et al (2015) Engineered CHO cells for production of diverse, homogeneous glycoproteins. Nat Biotechnol 33:842","journal-title":"Nat Biotechnol"},{"issue":"5","key":"132_CR168","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nbt.2893","volume":"32","author":"B Lepenies","year":"2014","unstructured":"Lepenies B, Seeberger PH (2014) Simply better glycoproteins. Nat Biotechnol 32(5):443\u2013445","journal-title":"Nat Biotechnol"},{"issue":"12","key":"132_CR169","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1007\/s000180050258","volume":"54","author":"C Traving","year":"1998","unstructured":"Traving C, Schauer R (1998) Structure, function and metabolism of sialic acids. Cell Mol Life Sci 54(12):1330\u20131349","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"132_CR170","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1749-6632.2012.06517.x","volume":"1253","author":"A Varki","year":"2012","unstructured":"Varki A, Gagneux P (2012) Multifarious roles of sialic acids in immunity. Ann N Y Acad Sci 1253(1):16\u201336","journal-title":"Ann N Y Acad Sci"},{"key":"132_CR171","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3389\/fimmu.2019.00807","volume":"10","author":"C Dhar","year":"2019","unstructured":"Dhar C, Sasmal A, Varki A (2019) From \u201cserum sickness\u201d to \u201cxenosialitis\u201d: past, present, and future significance of the non-human sialic acid Neu5Gc. Front Immunol 10:807","journal-title":"Front Immunol"},{"key":"132_CR172","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3389\/fimmu.2019.00789","volume":"10","author":"MO Altman","year":"2019","unstructured":"Altman MO, Gagneux P (2019) Absence of Neu5Gc and presence of anti-Neu5Gc antibodies in humans-an evolutionary perspective. Front Immunol 10:789","journal-title":"Front Immunol"},{"issue":"8","key":"132_CR173","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1038\/nbt.1651","volume":"28","author":"D Ghaderi","year":"2010","unstructured":"Ghaderi D, Taylor RE, Padler-Karavani V et al (2010) Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol 28(8):863\u2013867","journal-title":"Nat Biotechnol"},{"issue":"9","key":"132_CR174","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1002\/eji.200526146","volume":"35","author":"L Benatuil","year":"2005","unstructured":"Benatuil L, Kaye J, Rich RF et al (2005) The influence of natural antibody specificity on antigen immunogenicity. Eur J Immunol 35(9):2638\u20132647","journal-title":"Eur J Immunol"},{"issue":"23","key":"132_CR175","doi-asserted-by":"publisher","first-page":"3072","DOI":"10.1016\/j.vaccine.2009.03.019","volume":"27","author":"UM Abdel-Motal","year":"2009","unstructured":"Abdel-Motal UM, Wigglesworth K, Galili U (2009) Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-gal antibody. Vaccine 27(23):3072\u20133082","journal-title":"Vaccine"},{"issue":"4","key":"132_CR176","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.4049\/jimmunol.1303126","volume":"194","author":"JE Bakema","year":"2015","unstructured":"Bakema JE, Tuk CW, van Vliet SJ et al (2015) Antibody-opsonized bacteria evoke an inflammatory dendritic cell phenotype and polyfunctional Th cells by cross-talk between TLRs and FcRs. J Immunol 194(4):1856\u20131866","journal-title":"J Immunol"},{"issue":"1","key":"132_CR177","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3892\/ijmm.2015.2397","volume":"37","author":"G Huai","year":"2016","unstructured":"Huai G, Qi P, Yang H et al (2016) Characteristics of \u03b1-gal epitope, anti-gal antibody, \u03b11,3 galactosyltransferase and its clinical exploitation (review). Int J Mol Med 37(1):11\u201320","journal-title":"Int J Mol Med"},{"issue":"2","key":"132_CR178","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bbagen.2007.11.003","volume":"1780","author":"BA Macher","year":"2008","unstructured":"Macher BA, Galili U (2008) The Gal\u03b11,3Gal\u03b21,4GlcNAc-R (\u03b1-gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta 1780(2):75\u201388","journal-title":"Biochim Biophys Acta"},{"issue":"17","key":"132_CR179","doi-asserted-by":"publisher","first-page":"9131","DOI":"10.1128\/JVI.00647-07","volume":"81","author":"UM Abdel-Motal","year":"2007","unstructured":"Abdel-Motal UM, Guay HM, Wigglesworth K et al (2007) Immunogenicity of influenza virus vaccine is increased by anti-gal-mediated targeting to antigen-presenting cells. J Virol 81(17):9131\u20139141","journal-title":"J Virol"},{"issue":"14","key":"132_CR180","doi-asserted-by":"publisher","first-page":"6943","DOI":"10.1128\/JVI.00310-06","volume":"80","author":"U Abdel-Motal","year":"2006","unstructured":"Abdel-Motal U, Wang S, Lu S et al (2006) Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes. J Virol 80(14):6943\u20136951","journal-title":"J Virol"},{"issue":"7","key":"132_CR181","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.vaccine.2009.12.015","volume":"28","author":"UM Abdel-Motal","year":"2010","unstructured":"Abdel-Motal UM, Wang S, Awad A et al (2010) Increased immunogenicity of HIV-1 p24 and gp120 following immunization with gp120\/p24 fusion protein vaccine expressing alpha-gal epitopes. Vaccine 28(7):1758\u20131765","journal-title":"Vaccine"},{"issue":"11","key":"132_CR182","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S0264-410X(96)00300-3","volume":"15","author":"TR Henion","year":"1997","unstructured":"Henion TR, Gerhard W, Anaraki F et al (1997) Synthesis of alpha-gal epitopes on influenza virus vaccines, by recombinant alpha-1,3-galactosyltransferase, enables the formation of immune complexes with the natural anti-gal antibody. Vaccine 15(11):1174\u20131182","journal-title":"Vaccine"},{"issue":"4","key":"132_CR183","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/0264-410X(95)00189-8","volume":"14","author":"U Galili","year":"1996","unstructured":"Galili U, Repik PM, Anaraki F et al (1996) Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-gal antibody. Vaccine 14(4):321\u2013328","journal-title":"Vaccine"},{"issue":"3","key":"132_CR184","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jaci.2014.12.1947","volume":"135","author":"JW Steinke","year":"2015","unstructured":"Steinke JW, Platts-Mills TA, Commins SP (2015) The alpha-gal story: lessons learned from connecting the dots. J Allergy Clin Immunol 135(3):589\u2013596","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"132_CR185","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.alit.2019.04.001","volume":"68","author":"Y Chinuki","year":"2019","unstructured":"Chinuki Y, Morita E (2019) Alpha-gal-containing biologics and anaphylaxis. Allergol Int 68(3):296\u2013300","journal-title":"Allergol Int"},{"issue":"10","key":"132_CR186","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1111\/all.13873","volume":"74","author":"P Rom\u00e1n-Carrasco","year":"2019","unstructured":"Rom\u00e1n-Carrasco P, Lieder B, Somoza V et al (2019) Only \u03b1-gal bound to lipids, but not to proteins, is transported across enterocytes as an IgE-reactive molecule that can induce effector cell activation. Allergy 74(10):1956\u20131968","journal-title":"Allergy"},{"issue":"9","key":"132_CR187","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.addr.2013.05.007","volume":"65","author":"B Lepenies","year":"2013","unstructured":"Lepenies B, Lee J, Sonkaria S (2013) Targeting C-type lectin receptors with multivalent carbohydrate ligands. Adv Drug Del Rev 65(9):1271\u20131281","journal-title":"Adv Drug Del Rev"},{"issue":"8","key":"132_CR188","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1021\/acschembio.6b00265","volume":"11","author":"K Brzezicka","year":"2016","unstructured":"Brzezicka K, Vogel U, Serna S et al (2016) Influence of core beta-1,2-xylosylation on glycoprotein recognition by murine C-type lectin receptors and its impact on dendritic cell targeting. ACS Chem Biol 11(8):2347\u20132356","journal-title":"ACS Chem Biol"},{"key":"132_CR189","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/978-1-4939-2874-3_11","volume":"1331","author":"T Johannssen","year":"2015","unstructured":"Johannssen T, Lepenies B (2015) Identification and characterization of carbohydrate-based adjuvants. Methods Mol Biol 1331:173\u2013187","journal-title":"Methods Mol Biol"},{"key":"132_CR190","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jconrel.2013.12.011","volume":"175","author":"M Maglinao","year":"2014","unstructured":"Maglinao M, Eriksson M, Schlegel MK et al (2014) A platform to screen for C-type lectin receptor-binding carbohydrates and their potential for cell-specific targeting and immune modulation. J Control Release 175:36\u201342","journal-title":"J Control Release"},{"issue":"2","key":"132_CR191","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00418-016-1523-7","volume":"147","author":"S Mayer","year":"2017","unstructured":"Mayer S, Raulf M-K, Lepenies B (2017) C-type lectins: their network and roles in pathogen recognition and immunity. Histochem Cell Biol 147(2):223\u2013237","journal-title":"Histochem Cell Biol"},{"key":"132_CR192","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3389\/fimmu.2018.01261","volume":"9","author":"S Goyal","year":"2018","unstructured":"Goyal S, Castrillon-Betancur JC, Klaile E et al (2018) The interaction of human pathogenic fungi with C-type lectin receptors. Front Immunol 9:1261","journal-title":"Front Immunol"},{"issue":"2","key":"132_CR193","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.molimm.2012.10.031","volume":"55","author":"Y van Kooyk","year":"2013","unstructured":"van Kooyk Y, Unger WWJ, Fehres CM et al (2013) Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation. Mol Immunol 55(2):143\u2013145","journal-title":"Mol Immunol"},{"issue":"22","key":"132_CR194","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1002\/asia.201801088","volume":"13","author":"J Hu","year":"2018","unstructured":"Hu J, Wei P, Seeberger PH et al (2018) Mannose-functionalized nanoscaffolds for targeted delivery in biomedical applications. Chem Asian J 13(22):3448\u20133459","journal-title":"Chem Asian J"},{"issue":"2","key":"132_CR195","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S0304-4165(98)00126-3","volume":"1426","author":"TR Gemmill","year":"1999","unstructured":"Gemmill TR, Trimble RB (1999) Overview of N- and O-linked oligosaccharide structures found in various yeast species. Biochim Biophys Acta 1426(2):227\u2013237","journal-title":"Biochim Biophys Acta"},{"issue":"11","key":"132_CR196","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1099\/jmm.0.001062","volume":"68","author":"TJ Kottom","year":"2019","unstructured":"Kottom TJ, Hebrink DM, Monteiro JT et al (2019) Myeloid C-type lectin receptors that recognize fungal mannans interact with Pneumocystis organisms and major surface glycoprotein. J Med Microbiol 68(11):1649\u20131654","journal-title":"J Med Microbiol"},{"issue":"9","key":"132_CR197","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3390\/genes10090667","volume":"10","author":"G Angrand","year":"2019","unstructured":"Angrand G, Quill\u00e9v\u00e9r\u00e9 A, Loa\u00ebc N et al (2019) Sneaking out for happy hour: yeast-based approaches to explore and modulate immune response and immune evasion. Genes 10(9):667","journal-title":"Genes"},{"issue":"2","key":"132_CR198","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12833","volume":"91","author":"V Vetvicka","year":"2020","unstructured":"Vetvicka V, Vannucci L, Sima P (2020) Beta-glucan as a new tool in vaccine development. Scand J Immunol 91(2):e12833","journal-title":"Scand J Immunol"},{"issue":"1","key":"132_CR199","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/glycob\/cwh136","volume":"13","author":"P Stanley","year":"2003","unstructured":"Stanley P, Chen W (2003) Five Lec1 CHO cell mutants have distinct Mgat1 gene mutations that encode truncated N-acetylglucosaminyltransferase I. Glycobiology 13(1):43\u201350","journal-title":"Glycobiology"},{"issue":"8","key":"132_CR200","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.2005817","volume":"16","author":"G Byrne","year":"2018","unstructured":"Byrne G, O\u2019Rourke SM, Alexander DL et al (2018) CRISPR\/Cas9 gene editing for the creation of an MGAT1-deficient CHO cell line to control HIV-1 vaccine glycosylation. PLoS Biol 16(8):e2005817","journal-title":"PLoS Biol"},{"issue":"3","key":"132_CR201","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.biologicals.2009.02.014","volume":"37","author":"MMJ Cox","year":"2009","unstructured":"Cox MMJ, Hollister JR (2009) FluBlok, a next generation influenza vaccine manufactured in insect cells. Biologicals 37(3):182\u2013189","journal-title":"Biologicals"},{"issue":"5","key":"132_CR202","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0959-440X(02)00367-6","volume":"12","author":"IBH Wilson","year":"2002","unstructured":"Wilson IBH (2002) Glycosylation of proteins in plants and invertebrates. Curr Opin Struct Biol 12(5):569\u2013577","journal-title":"Curr Opin Struct Biol"},{"issue":"2","key":"132_CR203","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000096114","volume":"142","author":"F Altmann","year":"2007","unstructured":"Altmann F (2007) The role of protein glycosylation in allergy. Int Arch Allergy Immunol 142(2):99\u2013115","journal-title":"Int Arch Allergy Immunol"},{"issue":"7","key":"132_CR204","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/glycob\/cwt015","volume":"23","author":"S Gaunitz","year":"2013","unstructured":"Gaunitz S, Jin C, Nilsson A et al (2013) Mucin-type proteins produced in the Trichoplusia ni and Spodoptera frugiperda insect cell lines carry novel O-glycans with phosphocholine and sulfate substitutions. Glycobiology 23(7):778\u2013796","journal-title":"Glycobiology"},{"key":"132_CR205","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jprot.2015.05.030","volume":"126","author":"S Kurz","year":"2015","unstructured":"Kurz S, Aoki K, Jin C et al (2015) Targeted release and fractionation reveal glucuronylated and sulphated N- and O-glycans in larvae of dipteran insects. J Proteome 126:172\u2013188","journal-title":"J Proteome"},{"key":"132_CR206","first-page":"321","volume-title":"Essentials of glycobiology","author":"IBH Wilson","year":"2015","unstructured":"Wilson IBH, Cummings RD, Aebi M (2015) Chapter 25 \u2013 Nematoda. In: Varki A, Cummings RD, Esko JD et al (eds) Essentials of glycobiology, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 321\u2013333","edition":"3"},{"issue":"1","key":"132_CR207","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41467-018-07948-7","volume":"10","author":"F Martini","year":"2019","unstructured":"Martini F, Eckmair B, Stefanic S et al (2019) Highly modified and immunoactive N-glycans of the canine heartworm. Nat Commun 10(1):75","journal-title":"Nat Commun"},{"issue":"2","key":"132_CR208","doi-asserted-by":"publisher","first-page":"136","DOI":"10.7774\/cevr.2019.8.2.136","volume":"8","author":"BS Shim","year":"2019","unstructured":"Shim BS, Hong KJ, Maharjan PM et al (2019) Plant factory: new resource for the productivity and diversity of human and veterinary vaccines. Clin Exp Vaccine Res 8(2):136\u2013139","journal-title":"Clin Exp Vaccine Res"},{"issue":"5\u20136","key":"132_CR209","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/2051013615613272","volume":"3","author":"N Takeyama","year":"2015","unstructured":"Takeyama N, Kiyono H, Yuki Y (2015) Plant-based vaccines for animals and humans: recent advances in technology and clinical trials. Ther Adv Vaccine 3(5\u20136):139\u2013154","journal-title":"Ther Adv Vaccine"},{"issue":"5","key":"132_CR210","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/j.1467-7652.2009.00496.x","volume":"8","author":"M-A D\u2019Aoust","year":"2010","unstructured":"D\u2019Aoust M-A, Couture MMJ, Charland N et al (2010) The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J 8(5):607\u2013619","journal-title":"Plant Biotechnol J"},{"issue":"12","key":"132_CR211","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015559","volume":"5","author":"N Landry","year":"2010","unstructured":"Landry N, Ward BJ, Tr\u00e9panier S et al (2010) Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 5(12):e15559","journal-title":"PLoS One"},{"issue":"2","key":"132_CR212","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.clim.2014.08.003","volume":"154","author":"N Landry","year":"2014","unstructured":"Landry N, Pillet S, Favre D et al (2014) Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. Clin Immunol 154(2):164\u2013177","journal-title":"Clin Immunol"},{"issue":"5","key":"132_CR213","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/pbi.12301","volume":"13","author":"F Le Mauff","year":"2015","unstructured":"Le Mauff F, Mercier G, Chan P et al (2015) Biochemical composition of haemagglutinin-based influenza virus-like particle vaccine produced by transient expression in tobacco plants. Plant Biotechnol J 13(5):717\u2013725","journal-title":"Plant Biotechnol J"},{"issue":"9","key":"132_CR214","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1111\/pbi.12963","volume":"16","author":"E Margolin","year":"2018","unstructured":"Margolin E, Chapman R, Williamson A-L et al (2018) Production of complex viral glycoproteins in plants as vaccine immunogens. Plant Biotechnol J 16(9):1531\u20131545","journal-title":"Plant Biotechnol J"},{"issue":"46","key":"132_CR215","doi-asserted-by":"publisher","first-page":"6098","DOI":"10.1016\/j.vaccine.2014.08.079","volume":"32","author":"BJ Ward","year":"2014","unstructured":"Ward BJ, Landry N, Tr\u00e9panier S et al (2014) Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines. Vaccine 32(46):6098\u20136106","journal-title":"Vaccine"},{"issue":"7","key":"132_CR216","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/nbt.3556","volume":"34","author":"Y Shaaltiel","year":"2016","unstructured":"Shaaltiel Y, Tekoah Y (2016) Plant specific N-glycans do not have proven adverse effects in humans. Nat Biotechnol 34(7):706\u2013708","journal-title":"Nat Biotechnol"},{"issue":"10","key":"132_CR217","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186211","volume":"12","author":"B Rup","year":"2017","unstructured":"Rup B, Alon S, Amit-Cohen B-C et al (2017) Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems\u2014the taliglucerase alfa story. PLoS One 12(10):e0186211","journal-title":"PLoS One"},{"issue":"1","key":"132_CR218","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BST20170487","volume":"47","author":"DF Smith","year":"2019","unstructured":"Smith DF, Cummings RD, Song X (2019) History and future of shotgun glycomics. Biochem Soc Trans 47(1):1\u201311","journal-title":"Biochem Soc Trans"},{"issue":"2","key":"132_CR219","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/med.21625","volume":"40","author":"A Tamburrini","year":"2019","unstructured":"Tamburrini A, Colombo C, Bernardi A (2019) Design and synthesis of glycomimetics: recent advances. Med Res Rev 40(2):495\u2013531","journal-title":"Med Res Rev"},{"key":"132_CR220","doi-asserted-by":"publisher","unstructured":"Guan WJ, Ni ZY, Hu Y et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2002032","DOI":"10.1056\/NEJMoa2002032"},{"issue":"7798","key":"132_CR221","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu F, Zhao S, Yu B et al (2020) A new coronavirus associated with human respiratory disease in China. Nature 579(7798):265\u2013269","journal-title":"Nature"},{"issue":"12","key":"132_CR222","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1093\/glycob\/cwv091","volume":"25","author":"A Varki","year":"2015","unstructured":"Varki A, Cummings RD, Aebi M et al (2015) Symbol nomenclature for graphical representations of glycans. Glycobiology 25(12):1323\u20131324","journal-title":"Glycobiology"},{"issue":"6341","key":"132_CR223","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1126\/science.aam7260","volume":"356","author":"KM Hastie","year":"2017","unstructured":"Hastie KM, Zandonatti MA, Kleinfelter LM et al (2017) Structural basis for antibody-mediated neutralization of Lassa virus. Science 356(6341):923\u2013928","journal-title":"Science"},{"issue":"28","key":"132_CR224","doi-asserted-by":"publisher","first-page":"7320","DOI":"10.1073\/pnas.1803990115","volume":"115","author":"Y Watanabe","year":"2018","unstructured":"Watanabe Y, Raghwani J, Allen JD et al (2018) Structure of the Lassa virus glycan shield provides a model for immunological resistance. Proc Natl Acad Sci U S A 115(28):7320\u20137325","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7610","key":"132_CR225","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature18615","volume":"535","author":"Y Zhao","year":"2016","unstructured":"Zhao Y, Ren J, Harlos K et al (2016) Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 535(7610):169\u2013172","journal-title":"Nature"},{"issue":"1","key":"132_CR226","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1038\/ncomms4614","volume":"5","author":"PS Lee","year":"2014","unstructured":"Lee PS, Ohshima N, Stanfield RL et al (2014) Receptor mimicry by antibody F045-092 facilitates universal binding to the H3 subtype of influenza virus. Nat Commun 5(1):3614","journal-title":"Nat Commun"},{"issue":"9","key":"132_CR227","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1021\/acs.jproteome.5b00416","volume":"14","author":"Y An","year":"2015","unstructured":"An Y, McCullers JA, Alymova I et al (2015) Glycosylation analysis of engineered H3N2 influenza A virus hemagglutinins with sequentially added historically relevant glycosylation sites. J Proteome Res 14(9):3957\u20133969","journal-title":"J Proteome Res"},{"issue":"8","key":"132_CR228","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1016\/j.celrep.2018.07.080","volume":"24","author":"WB Struwe","year":"2018","unstructured":"Struwe WB, Chertova E, Allen JD et al (2018) Site-specific glycosylation of virion-derived HIV-1 Env is mimicked by a soluble trimeric immunogen. Cell Rep 24(8):1958\u20131966.e1955","journal-title":"Cell Rep"},{"issue":"7","key":"132_CR229","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/nsmb.3051","volume":"22","author":"YD Kwon","year":"2015","unstructured":"Kwon YD, Pancera M, Acharya P et al (2015) Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol 22(7):522\u2013531","journal-title":"Nat Struct Mol Biol"},{"issue":"10","key":"132_CR230","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nsmb.3293","volume":"23","author":"AC Walls","year":"2016","unstructured":"Walls AC, Tortorici MA, Frenz B et al (2016) Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nat Struct Mol Biol 23(10):899\u2013905","journal-title":"Nat Struct Mol Biol"},{"issue":"12","key":"132_CR231","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005322","volume":"11","author":"K Xu","year":"2015","unstructured":"Xu K, Chan YP, Bradel-Tretheway B et al (2015) Crystal structure of the pre-fusion Nipah virus fusion glycoprotein reveals a novel hexamer-of-trimers assembly. PLoS Pathog 11(12):e1005322","journal-title":"PLoS Pathog"}],"container-title":["Advances in Biochemical Engineering\/Biotechnology","Advances in Glycobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/10_2020_132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T21:44:55Z","timestamp":1723585495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/10_2020_132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030695897","9783030695903"],"references-count":231,"URL":"https:\/\/doi.org\/10.1007\/10_2020_132","relation":{},"ISSN":["0724-6145","1616-8542"],"issn-type":[{"value":"0724-6145","type":"print"},{"value":"1616-8542","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"16 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}